Stanford stem cell product, delayed for more than a decade, to be tested again

A 1990s innovation, bought and then abandoned by a biotech company, is back in the hands of frustrated scientist Irving Weissman. Early trials showed its promise against advanced cancer -- so he's thrilled to finally resume research on a university campus where 'medical need, rather than rapid profits' is what matters.
Read more: http://ift.tt/1R3ZgS1